BACKGROUND: Thrombosis of synthetic small-diameter bypass grafts remains a major problem. The aim of this article is to review the antithrombotic strategies that have been used in an attempt to reduce graft thrombogenicity. METHODS: A PubMed/MEDLINE search was performed using the search terms "vascular graft thrombosis," "small-diameter graft thrombosis," "synthetic graft thrombosis" combined with "antithrombotic," "antiplatelet," "anticoagulant," "Dacron," "PTFE," and "polyurethane." RESULTS: The majority of studies on antithrombotic therapies have used either in vitro models or in vivo animal experiments. Many of the therapies used in these settings do show antithrombotic efficacy against synthetic graft materials. There is however, a distinct lack of human in vivo studies to further delineate the performance and limitations of therapies displaying good antithrombotic characteristics. CONCLUSION: Very few antithrombotic therapies have translated into clinical use. More human in vivo studies are required to assess the efficacy and safety of such therapies.
BACKGROUND:Thrombosis of synthetic small-diameter bypass grafts remains a major problem. The aim of this article is to review the antithrombotic strategies that have been used in an attempt to reduce graft thrombogenicity. METHODS: A PubMed/MEDLINE search was performed using the search terms "vascular graft thrombosis," "small-diameter graft thrombosis," "synthetic graft thrombosis" combined with "antithrombotic," "antiplatelet," "anticoagulant," "Dacron," "PTFE," and "polyurethane." RESULTS: The majority of studies on antithrombotic therapies have used either in vitro models or in vivo animal experiments. Many of the therapies used in these settings do show antithrombotic efficacy against synthetic graft materials. There is however, a distinct lack of human in vivo studies to further delineate the performance and limitations of therapies displaying good antithrombotic characteristics. CONCLUSION: Very few antithrombotic therapies have translated into clinical use. More human in vivo studies are required to assess the efficacy and safety of such therapies.
Authors: Jennifer M Bastijanic; Roger E Marchant; Faina Kligman; Matthew T Allemang; Ryan O Lakin; Daniel Kendrick; Vikram S Kashyap; Kandice Kottke-Marchant Journal: J Vasc Surg Date: 2015-03-28 Impact factor: 4.268
Authors: Megan Kimicata; Jules D Allbritton-King; Javier Navarro; Marco Santoro; Takahiro Inoue; Narutoshi Hibino; John P Fisher Journal: Acta Biomater Date: 2020-04-16 Impact factor: 8.947
Authors: Maria A Rodriguez-Soto; Andres J Garcia-Brand; Alejandra Riveros; Natalia A Suarez; Fidel Serrano; Johann F Osma; Carolina Muñoz Camargo; Juan C Cruz; Nestor Sandoval; Juan C Briceño Journal: Polymers (Basel) Date: 2022-05-24 Impact factor: 4.967
Authors: Mehmet H Kural; Yuling Li; Juan Wang; Kaleb M Naegeli; Emmanuelle A Hugentobler; Laura E Niklason Journal: Circ Res Date: 2022-06-23 Impact factor: 23.213
Authors: Ryan A Hoshi; Robert Van Lith; Michele C Jen; Josephine B Allen; Karen A Lapidos; Guillermo Ameer Journal: Biomaterials Date: 2012-10-12 Impact factor: 12.479
Authors: Zheng Qu; Venkat Krishnamurthy; Carolyn A Haller; Brent M Dorr; Ulla M Marzec; Sawan Hurst; Monica T Hinds; Stephen R Hanson; David R Liu; Elliot L Chaikof Journal: Adv Healthc Mater Date: 2013-06-21 Impact factor: 9.933
Authors: Larisa V Antonova; Victoria V Sevostyanova; Anton G Kutikhin; Andrey V Mironov; Evgeniya O Krivkina; Amin R Shabaev; Vera G Matveeva; Elena A Velikanova; Evgeniya A Sergeeva; Andrey Y Burago; Georgiy Y Vasyukov; Tatiana V Glushkova; Yuliya A Kudryavtseva; Olga L Barbarash; Leonid S Barbarash Journal: Front Pharmacol Date: 2016-07-29 Impact factor: 5.810